The chances of the French drug company muscling in on Johnson & Johnson's talks with Actelion are slim, based on Sanofi's cost of capital vs. return from a possible deal.
- Zacks•2 days ago
This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.
- Motley Fool•2 days ago
While attempting to offset biosimilar competition on their best-selling drugs, J&J and Sanofi could be making a big mistake by chasing Actelion.
ALIOF : Summary for ACTELION LTD CHF0.50 (REGD) - Yahoo Finance
Actelion Ltd. (ALIOF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||198.65 - 202.49|
|52 Week Range||138.01 - 208.83|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.21|
|Dividend & Yield||1.54 (0.75%)|
|1y Target Est||N/A|